Events

AI3SD Winter Seminar w/ Sia Togia

Natural Language Processing in AI-driven drug discovery; what it is, why it matters and how (not) to do it

Natural Language Processing (NLP) has been used in drug discovery for decades. However, the emergence of AI-driven drug discovery coupled with recent advances in NLP have redefined the relationship between the two fields. This talk will focus on major classes of NLP techniques used in drug discovery as well as challenges arising when creating real-world biomedical NLP systems. The talk will cover topics such as dataset selection and construction, evaluation, models, methodology, research process and structure of NLP systems in AI-driven drug discovery.

Register →





Sia Togia

Lead AI Scientist

I am a Lead AI Scientist at BenevolentAI with a focus on NLP. I have a PhD in NLP from the University of Cambridge and have spent the last six years building NLP systems in the AI industry, mostly in the biomedical domain. I specialise in Information Extraction, Information Retrieval and Knowledge Representation and have a strong interest in creating NLP systems that solve real-world problems.

More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021